Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib

Irene Bargellini, Antonio Gasbarrini

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)1-N/A
JournalCancer Imaging
Volume22
DOIs
Publication statusPublished - 2022

Keywords

  • Early tumor shrinkage
  • Hepatocellular carcinoma
  • Objective response
  • Sorafenib
  • mRECIST

Cite this